HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Eyes Limiting Natural Claim For Benefiber Following Industry Self-Regulation Ad Review

Executive Summary

BBB National Programs' appellate panel finds GSK supports “helps you feel fuller longer” claim but not “clinically proven to curb cravings” for Benefiber supplements. GSK will comply with recommendation to pull "100% natural claim" but notes the panel recognized it “can make a more limited or qualified ‘natural’ claim that is supported by the evidence."

You may also be interested in...



J&J’s Zarbee’s Natural Business Stung By P&G Challenge To Using ‘Natural’ In Brand Name

NAD recommends qualifying Zarbee’s Naturals brand on packaging when a formulation contains synthetic ingredients. J&J business will comply but disagrees its brand is misleading and says the recommendation is “not based on empirical data from consumers surveys” but NAD attorneys’ intuition.

US FDA’s 30-Day Extension For Nitrosamine Assessments Short Of Industry Recommendation

Revision to FDA's September 2020 guidance on assessing nitrosamine impurity risks associated with all chemically synthesized APIs and all approved drug products that contain those APIs doesn’t satisfy industry stakeholders.

With Timetable In Hand And Icahn On Board, Bausch Health Looks To ‘Expedite Spin-Off’

Executives say Bausch + Lomb spin-out preparations will be completed by the end of Q3. When asked, they elaborated on Carl Icahn’s acquisition of 27.8m shares, for a 7.8% stake, and expansion of the firm’s board by two seats for Icahn’s representatives.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel